Le Ngoc Duong

US Patent:

20020040039, Apr 4, 2002

Filed:

Sep 18, 2001

Appl. No.:

09/955379

Inventors:

George Hartman - Lansdale PA, US
Mark Duggan - Schwenksville PA, US
Gideon Rodan - Bryn Mawr PA, US
Sevgi Rodan - Bryn Mawr PA, US
Le Duong - Lansdale PA, US
Donald Kimmel - Doylestown PA, US

International Classification:

A61K031/443
A61K031/415
A61K031/365

US Classification:

514/336000, 514/406000, 514/473000

Abstract:

The present invention provides for methods for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a cyclooxygenase-2 specific inhibitor in combination with an , and/or integrin receptor antagonist in an amount effective to treat or prevent the inflammatory disease or condition. The present invention also provides for pharmaceutical compositions for the treatment or prevention of an inflammatory disease or condition. Further, the invention provides for the manufacture of a medicament useful in the treatment or prevention of an inflammatory disease or condition.

US Patent:

20050004199, Jan 6, 2005

Filed:

Sep 14, 2001

Appl. No.:

10/380785

Inventors:

George Hartman - Lansdale PA, US
Mark Duggan - Schwenksville PA, US
Gideon Rodan - Bryn Mawr PA, US
Sevgi Rodan - Bryn Mawr PA, US
Le Duong - Lansdale PA, US
Donald Kimmel - Doylestown PA, US

International Classification:

A61K031/415
A61K031/365

US Classification:

514406000, 514473000

Abstract:

The present invention provides for methods for treating or preventing an inflammatory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a cyclooxygenase-2 specific inhibitor in combination with an αβ, V5? and/or αβintegrin receptor antagonist in an amount effective to treat or prevent the inflammatory disease or condition. The present invention also provides for pharmaceutical compositions for the treatment or prevention of an inflammatory disease or condition. Further, the invention provides for the manufacture of a medicament useful in the treatment or prevention of an inflammatory disease or condition.

US Patent:

20060040298, Feb 23, 2006

Filed:

Aug 5, 2005

Appl. No.:

11/198640

Inventors:

Azriel Schmidt - Bryn Mawr PA, US
Le Duong - Lansdale PA, US
Maureen Pickarski - Ambler PA, US

International Classification:

C12Q 1/68
G01N 33/53
C07H 21/04
C12P 21/06
C12N 5/06
C07K 14/72
C07K 16/28

US Classification:

435006000, 435069100, 435007100, 435320100, 435363000, 530350000, 536023500, 530388220

Abstract:

The (rhesus monkey) NURR1 nuclear receptor and the nucleic acid encoding the rhesus monkey NURR1 are described. Further described are methods for identifying analytes which modulate expression or activity of the rhNURR1 for treating or inhibiting inflammatory diseases such as osteoarthritis, bone disorders, neurological such as Parkinson's disease, psychotic diseases such as bipolar diseases, and prostate disorders.

US Patent:

20070004681, Jan 4, 2007

Filed:

Mar 23, 2004

Appl. No.:

10/550532

Inventors:

Le Duong - Lansdale PA, US
Tadashi Hayami - Lansdale PA, US
Anatasia Daifotis - Westfield NJ, US
Gideon Rodan - Bryn Mawr PA, US

International Classification:

A61K 31/675
A61K 31/663

US Classification:

514089000, 514102000

Abstract:

The present invention relates to a method for eliciting a disease modifying effect on an arthritic condition in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound. The present invention also relates to method for eliciting a disease modifying effect on subchondral bone sclerosis, preventing osteophyte formation or progression and preventing joint destruction in a mammal which comprises administering to the mammal a therapeutically effective amount of an anti-resorptive compound.

US Patent:

20070122849, May 31, 2007

Filed:

Nov 29, 2006

Appl. No.:

11/605677

Inventors:

Norbert Peekhaus - Harleysville PA, US
Herbert Dang - Doylestown PA, US
Le Duong - Lansdale PA, US

International Classification:

G01N 33/53
C07H 21/04
C12P 21/06
C07K 14/705
C12N 5/06
C12N 5/08

US Classification:

435007100, 435069100, 435320100, 435325000, 435362000, 435369000, 530350000, 536023500

Abstract:

A P2X7 purinergic receptor has been isolated from the genome of (Rhesus monkey). Described is the amino acid sequence of the receptor, the nucleic acid encoding the receptor, and methods for using the receptor to identify analytes that are agonists or antagonists of the receptor.

US Patent:

60571136, May 2, 2000

Filed:

Dec 22, 1998

Appl. No.:

9/218242

Inventors:

Le T. Duong - Jenkintown PA
Gideon A. Rodan - Bryn Mawr PA
Elka M. Nutt - Lansdale PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 14715

US Classification:

435 71

Abstract:

The full-length mouse. beta. 3 integrin has been cloned and sequenced. A new form of. beta. 3 integrin (. beta. 3-trunc also been cloned and sequenced.

US Patent:

58308490, Nov 3, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/467966

Inventors:

Richard A. F. Dixon - Lansdale PA
Stephen J. Gardell - North Wales PA
Le Thi Duong - Jenkintown PA
Paul A. Friedman - Rosemont PA
John W. Jacobs - Doylestown PA
George E. Mark - Princeton Junction NJ
Bruce L. Daugherty - South Orange NJ

Assignee:

Schering Aktiengesellschaft - Berlin

International Classification:

C12N 121
C12N 1512
C12N 964
A61K 3843

US Classification:

514 2

Abstract:

Purified plasminogen activator proteins obtained or derived from the vampire bat Desmodus rotundus saliva and salivary glands, methods for purifying the proteins, DNA sequences encoding these proteins, means for producing them using recombinant DNA technology, pharmaceutical compositions comprising these proteins and methods of treatment utilizing these proteins are provided.

US Patent:

50875612, Feb 11, 1992

Filed:

Jun 28, 1990

Appl. No.:

7/545256

Inventors:

Michael Rosenblatt - Ardmore PA
Michael Chorev - Jerusalem, IL
Eliahu Roubini - Lensvale PA
Ruth F. Nutt - Green Lane PA
Le T. Duong - Jenkintown PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

G01N 33567
C07K 710
A61K 3724

US Classification:

435 721

Abstract:

The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human humoral hypercalcemic factor (hHCF), wherein Lys. sup. 13 or Lys. sup. 11 is modified on the epsilon-amino group by biotin so as to produce HCF analogues which can inhibit the action of HCF.